HLB(028300) Group recently appointed Kim Do-yeon, former president of HLB Life Sciences, as the new co-CEO of HLB Genex, a company specializing in industrial enzymes, on the 13th. CEO Kim Do-yeon will oversee the management sector, while the existing CEO Kim Ui-jung will handle the business sector as co-CEOs.
On the 12th, HLB Genex held an extraordinary general meeting and changed its name to HLB Genex. The board of directors now includes President Kim Do-yeon, Chairman Jin Yang-gon of HLB Group, CEO Kim Song-su of HLB Barabaio, and CEO Sim Gyeong-jae of HLB Neurotov. The outside directors include former Money Today executive Kim Jun-hyung, advisor Lee Sang-baek of Da ITI Co., Ltd., and adviser Ko Hoon of China Buchang Pharmaceutical.
CEO Kim Do-yeon is a financial and investment expert who graduated from Seoul National University with a degree in business administration and worked at Samil Accounting Corporation managing audits and taxes, as well as corporate finance. In 2016, he served as vice president of management at Zenbody, a company specializing in diagnostic kits, gaining experience in the healthcare field. He joined HLB Group in 2021, serving as Chief Operating Officer, and was appointed as Vice President of Business Management at HLB Life Sciences in July of this year. Recently, he was promoted to president in HLB Group's annual personnel reshuffle.
CEO Kim Do-yeon noted, "As HLB Genex possesses unique enzyme production technology based on microbial display technology, we will focus on product expansion and entering the global market in the future."